Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Bayer Lynkuet approved in EU for hot flashes

Ruchika Sharma20 Nov 2025 10:30 AM IST

Berlin: Bayer has announced that the European Commission has granted marketing authorization in the European Union (EU) for elinzanetant, under...

AbbVie gets USFDA nod for Epkinly, Rituximab, Lenalidomide combo for Follicular Lymphoma

Ruchika Sharma19 Nov 2025 4:15 PM IST

North Chicago: AbbVie has announced that EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination...

Show cause notices issued to 196 retail medical shops in Telangana

Ruchika Sharma19 Nov 2025 3:18 PM IST

Telangana: In a sweeping statewide crackdown, the Drugs Control Administration, Telangana, has issued show cause notices to 196 retail medical...

Syngene International appoints Dr Rohtash Kumar as Head of CDMO, Small and Large Molecule

Ruchika Sharma19 Nov 2025 2:15 PM IST

Karnataka: Syngene International has announced the appointment of Dr Rohtash Kumar as Head of CDMO, Small and Large Molecule and a member of...

Solara Active Pharma Sciences Mangalore facility successfully completes USFDA inspection

Ruchika Sharma19 Nov 2025 1:03 PM IST

Chennai: Solara Active Pharma Sciences Limited, an Active Pharmaceutical Ingredient provider, has announced that its multi-product manufacturing...

USFDA approves Marksans Pharma anti-diarrheal medication

Ruchika Sharma19 Nov 2025 12:47 PM IST

Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the US Food and...

Biocon expects 50 percent drop in costs for developing complex biosimilars: Top executive

Biocon Pharma gets USFDA nod for arthritis drug Tofacitinib ER

Ruchika Sharma19 Nov 2025 11:15 AM IST

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval from the U.S...

$Roche Lunsumio subcutaneous secures European Commission approval for refractory follicular lymphoma$

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok

Articles By : Ruchika Sharma

Bayer Lynkuet approved in EU for hot flashes

AbbVie gets USFDA nod for Epkinly, Rituximab, Lenalidomide combo for Follicular Lymphoma

Show cause notices issued to 196 retail medical shops in Telangana

Syngene International appoints Dr Rohtash Kumar as Head of CDMO, Small and Large Molecule

Solara Active Pharma Sciences Mangalore facility successfully completes USFDA inspection

USFDA approves Marksans Pharma anti-diarrheal medication

Biocon Pharma gets USFDA nod for arthritis drug Tofacitinib ER

Roche Lunsumio subcutaneous secures European Commission approval for refractory follicular lymphoma

Dr Ajay Sharma to resign as Director - Corporate Affairs of AstraZeneca Pharma India

Eli Lilly Donanemab secures CDSCO nod for early symptomatic Alzheimer's Disease

Hetero appoints Kshitiz Gadodia to Global Team as President - Finance & Accounts

Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3 trial